Colistin-based regimens showed a significant advantage (p = 0.03) in bloodstream infections caused by CP-CRE, whereas regimens containing tigecycline showed some advantage in pneumonia caused by CP-CRE, although this was not statistically significant (p = 0.28). This evidence concerns the gene CP and pneumonia.